Key facts
- Biotech experts and industry executives are calling for the FDA to ensure politics does not interfere with drug reviews.
- The FDA has experienced significant employee departures, impacting leadership and expertise.
- Concerns have been raised about political appointees influencing key drug and vaccine decisions.
- The FDA has announced plans to hire thousands of employees and shorten clinical trial timelines.
- Several potential candidates are being considered for the FDA commissioner position.
Biotech experts and industry executives are expressing a desire for the U.S. Food and Drug Administration (FDA) to prioritize scientific integrity in its drug review processes, particularly as the agency plans to hire thousands of employees and update clinical-trial standards. Concerns have been amplified by recent leadership changes and alleged political interference within the FDA.
Industry figures like John Guy of the Incubate Coalition emphasize the need for regulatory predictability to ensure scientific advancements reach patients, advocating for the rebuilding of durable scientific expertise at the agency. John Crowley, CEO of the BIO industry trade group, characterized the significant employee cuts experienced by the FDA as a "DOGE wrecking ball," referring to the Trump administration's Department of Government Efficiency, and stressed the need for standardized review processes.
Several former agency officials, including long-time cancer division head Richard Pazdur, have voiced concerns that key decisions on drugs and vaccines have been influenced by political appointees rather than solely by scientific judgment. This sentiment is underscored by the departures of former Commissioner Marty Makary and biologics division chief Vinay Prasad amid controversies. The FDA's primary drug-review division has seen frequent leadership changes since the start of President Donald Trump's second term in January 2025, with a temporary director currently leading the arm.
In response to these challenges and global competition, the FDA has announced plans to recruit 2,200 new employees and accelerate development timelines for cell and gene therapies. Paul Hastings, CEO of Nkarta, highlighted the agency's focus on cell therapy, emphasizing the importance of maintaining a leading position. While the FDA has largely maintained its drug approval pace, investors are closely monitoring the situation.
The administration is reportedly considering three candidates for the FDA commissioner role: White House domestic policy aide Heidi Overton, oncologist Jeffrey Vacirca, and Pentagon health official Stephen Ferrara. Former FDA Commissioner Scott Gottlieb has called for reinstating experienced scientific and clinical experts in leadership positions, suggesting a need to redefine the boundary between political power and scientific judgment. A Department of Health and Human Services spokesperson, Emily Hilliard, stated that accusations of political influence misrepresent the FDA's review process and the work of its dedicated staff.
Past incidents, such as the initial refusal to review Moderna's mRNA flu vaccine and public criticism of a Huntington's disease treatment application, have fueled perceptions of unfair treatment for drugmakers and patients. Experts like Paul Wotton of RBL Ventures suggest that innovation in evaluation methods and standardization of review criteria are crucial. While some companies like Kyverna have not been directly impacted by the agency's upheaval, the situation has raised questions about the future pathway for certain therapies. Elizabeth Jungman, a regulatory attorney, noted that the traditional barrier between FDA leadership and drug reviews has been compromised, and the restoration of the scientific staff's role remains uncertain.